Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study

Arenberger, Petr; Hladíková, Marie; Holcova, S.; Ottillinger, Bertram

doi:10.1016/j.curtheres.2017.10.004

Cited by 14 publications

(19 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the abovementioned T2DM, there was an improvement in the cognitive pattern in patients with Alzheimer's disease, associated with a reduction in inflammatory markers [ 4 ]. Clinical trials have shown the efficacy of propolis in the treatment of oral diseases associated with herpesvirus type I [ 34 ] and others, such as prosthetic stomatitis [ 35 ], recurrent cold sore [ 36 ], and periodontal disease, and the reduction of oxidative stress was shown in this last study [ 37 ]. Regarding EPP-AF®, a clinical trial with chronic renal patients with proteinuria showed a reduction in monocyte chemoattractant protein-1 (MCP-1), which is a marker of inflammation and proteinuria intensity [ 38 ].…”

Section: Discussionmentioning

confidence: 81%

Antioxidant Effect of Standardized Extract of Propolis (EPP‐AF®) in Healthy Volunteers: A “Before and After” Clinical Study

Diniz

Lorencini

Berretta

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Propolis is rich in polyphenols, especially flavonoids and phenolic acids, and has significant antioxidant activity, shown mainly in “in vitro” studies. Objective. The aim of this study was to evaluate the antioxidant efficacy and safety of a standardized propolis extract in healthy volunteers. Design. A two-phase sequential, open-label, nonrandomized, before and after clinical trial. Methods. Healthy participants received two EPP-AF® doses (375 and 750 mg/d, P.O, tid) during 7 ± 2 days, starting with the lower doses. Immediately before starting EPP-AF® administration and at the end of each 7-day dosing schedule, blood and urine samples were collected for quantification of 8-OHDG (8-hydroxydeoxyguanosine) and 8-ISO (8-isoprostanes) in urine and GSH (reduced glutathione), GSSG (oxidized glutathione), SOD (superoxide dismutase), FRAP (Ferric Reducing Antioxidant Power), vitamin E, and MDA (malondialdehyde) in plasma. Results. In our study, we had 34 healthy participants (67.7% women, 30 ± 8 years old, 97% white). The 8-ISO, a biomarker of lipid peroxidation, decreased with both doses of EPP-AF® compared to baseline (8-ISO, 1.1 (0.9–1.3) versus 0.85 (0.75–0.95) and 0.89 (0.74–1.0), ng/mg creatinine, P < 0.05 , for 375 and 750 mg/d EPP-AF® doses versus baseline, mean and CI 95%, respectively). 8-OHDG, a biomarker of DNA oxidation, was also reduced compared to baseline with 750 mg/d doses (8-OHDG, 15.7 (13.2–18.1) versus 11.6 (10.2–13.0), baseline versus 750 mg/d, respectively, ng/mg creatinine, P < 0.05 ). Reduction of biomarkers of oxidative stress damage was accompanied by increased plasma SOD activity (68.8 (66.1–73.3) versus 78.2 (72.2–80.5) and 77.7 (74.1–82.6), %inhibition, P < 0.0001 , 375 and 750 mg/d versus baseline, median and interquartile range 25–75%, respectively) and by increased GSH for 375 mg/d EPP-AF® doses (1.23 (1.06–1.34) versus 1.33 (1.06–1.47), μmol/L, P < 0.05 ). Conclusion. EPP-AF® reduced biomarkers of oxidative stress cell damage in healthy humans, with increased antioxidant enzymatic capacity, especially of SOD. This trial is registered with the Brazilian Registry of Clinical Trials (ReBEC, RBR-9zmfs9).

show abstract

Section: Discussionmentioning

confidence: 81%

Antioxidant Effect of Standardized Extract of Propolis (EPP‐AF®) in Healthy Volunteers: A “Before and After” Clinical Study

Diniz

Lorencini

Berretta

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The classical local therapy for herpes labialis is carried out with virostatics such as aciclovir or penciclovir. With substances of the aciclovir type, whose effect is exclusively based on an antiviral activity [ 3 – 7 ], we found that a truly satisfactory local therapy of the debilitating and painful herpes labialis is not ensured [ 8 , 9 ]. Active substances that, apart from the antiviral properties, also show antibacterial, antiphlogistic and, if possible, also local anesthetizing effects could be advantageous in the management of herpes labialis.…”

Section: Introductionmentioning

confidence: 99%

“…Dermatological studies [ 8 , 29 ] performed with the special propolis extract GH 2002 (with pollen, waxes and resins removed to reduce the risk of allergic reactions) confirm the in vitro results and verified that significant results were achieved in the treatment of herpes labialis, applying 0.5% of this active substance in a cream. Recently, a single-blind study in 379 herpes labialis patients showed significant therapeutic results in favor of a cream with 0.5% GH 2002 compared with aciclovir cream 5%, both for the primary parameter incrustation/healing and for the secondary parameters pain, itching, swelling and tension [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Lip creams with propolis special extract GH 2002 0.5% versus aciclovir 5.0% for herpes labialis (vesicular stage)

Jautová

Zelenkova²,

Drotarová³

et al. 2018

Wien Med Wochenschr

View full text Add to dashboard Cite

Summary A lip cream with special propolis extract GH 2002 at a concentration of 0.5% (199 patients) was tested against aciclovir 5% (198 patients) in the treatment of episodes of herpes labialis under double-blind conditions. Upon inclusion, all patients were in the vesicular phase. Application was five times daily of approximately 0.2 g of cream to the entire upper and lower lip. The primary parameter was the difference in time between groups to complete encrustation or epithelization of the lesions. Secondary endpoints were the course of typical herpes symptoms (pain, burning and itching, tension and swelling), the global assessment of efficacy and the safety of application. The predefined clinical situation was reached after a (median) 3 days with propolis and 4 days with aciclovir ( p < 0.0001). Significant differences in favor of propolis were also found for all secondary parameters. No allergic reactions, local irritations or other adverse events occurred.

show abstract

“…With every replacement, already formed crusts were torn off with the patch, causing pain while promoting primary wound healing. Accompanying symptoms such as pain, tingling, swelling, or burning were also assessed in comparable trials 43,44 . The duration and intensity of symptoms were rated and showed comparable distributions independent of the applied product.…”

Section: Discussionmentioning

confidence: 99%

Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis

Boes

Goulioumis

Wechsler

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Herpes simplex labialis (HSL) is a viral disease that affects the perioral region. No guidelines recommending an effective treatment exist. The treatment of HSL with three different products was examined. Herpatch Serum, a film-forming patch, was compared to Compeed Patches, a set of semiocclusive hydrocolloid patches, and Zovirax Cream (ingredient: 5% acyclovir). In this prospective, randomized, examiner-blind study, 180 patients with recurrent HSL were split into three groups (Compeed: n = 60, Herpatch: n = 60, Zovirax: n = 60) and examined within 24 hours of HSL outbreak (DRKS Registration No.: DRKS00007786). The primary endpoint was healing time. The secondary endpoints were the reaction rate and quality of therapy evaluated by the Clinician's Global Assessment of Therapy (CGAT) and the Subject's Global Assessment of Therapy (SGAT) (0 = no response; 10 = excellent response), respectively. There was no significant difference among the healing times for the different products. The mean (95% confidence interval) was 9.67 days (9.11-10.22) for Compeed, 9.30 days (8.75-9.85) for Herpatch, and 9.80 days (9.30-10.30) for Zovirax. The reaction rate and quality of therapy (CGAT and SGAT) of Herpatch were significantly higher than those of Compeed and Zovirax. Within the study limitations, Herpatch proved to be an effective, non-antiviral alternative in the treatment of HSL.Herpes simplex labialis (HSL) is a worldwide infection of the oral and perioral regions caused by an infection with Herpes Simplex Virus type 1 (HSV-1) or, rarely, Herpes Simplex Virus type 2 (HSV-2). Despite the high prevalence of HSL, the disease has not yet been well characterized. The seroprevalence of HSV-1 in Germany was 78.4% from 2008 until 2011 1,2 . While many infections remain subclinical, other patients suffer from painful recurrent infections.Following the primary infection with HSV-1, the virus replicates at the site of infection and proceeds to travel retrograde down unmyelinated sensory fibres to the trigeminal ganglion, where it establishes latency 3 . Interfering triggers such as psychological or physiological stress, UVB radiation, trauma, menstruation, sideropenia or febrile illness can provoke the reactivation of the virus 4,5 .The course of disease in recurrent HSL generally involves several stages. Within the precursor stage, pain, tingling, or burning sensations in the affected area may occur. This is followed by the appearance of a macule, turning into a papule and leading to the formation of a vesicle. The vesicle bursts, and the formation of a soft scab is initiated. Subsequently, the soft scab is replaced by a hard scab. Over time, the scab falls off, and the lesion is fully healed without scarring 6-8 . While healing, the process is often accompanied by symptoms such as pain, discomfort or reduced self-esteem 6 . Complete healing takes seven to ten days 7 .The treatment of recurrent HSL turns out to be very difficult and variable. Because of the slight effects of diverse therapies, the infection represents a constant and...

show abstract

Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study

Cited by 14 publications

References 9 publications

Antioxidant Effect of Standardized Extract of Propolis (EPP‐AF®) in Healthy Volunteers: A “Before and After” Clinical Study

Antioxidant Effect of Standardized Extract of Propolis (EPP‐AF®) in Healthy Volunteers: A “Before and After” Clinical Study

Lip creams with propolis special extract GH 2002 0.5% versus aciclovir 5.0% for herpes labialis (vesicular stage)

Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis

Contact Info

Product

Resources

About